University of Texas MD Anderson Cancer Center-ko ikertzaileekin lankidetzan egindako argitalpenak (45)

2024

  1. Consensus on surgical technique for sentinel lymph node dissection in cervical cancer

    International Journal of Gynecological Cancer, Vol. 34, Núm. 4, pp. 504-509

  2. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Journal of Clinical Oncology, Vol. 42, Núm. 1, pp. 47-58

  3. Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02

    Advances in Therapy

2023

  1. Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis

    Gynecologic Oncology, Vol. 177, pp. 157-164

  2. Outcomes and endpoints of relevance in gynecologic cancer clinical trials

    International Journal of Gynecological Cancer, Vol. 33, Núm. 3, pp. 323-332

2022

  1. A Comment on a Recent Failed HIPEC Trial

    Annals of Surgical Oncology

  2. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

    The Lancet Oncology, Vol. 23, Núm. 8, pp. e374-e384

  3. Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma

    New England Journal of Medicine, Vol. 386, Núm. 26, pp. 2471-2481

2021

  1. Corrigendum to ‘The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148–1159] (Annals of Oncology (2020) 31(9) (1148–1159), (S0923753420398914), (10.1016/j.annonc.2020.06.004))

    Annals of Oncology

  2. Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

    Journal of Clinical Oncology, Vol. 39, Núm. 1, pp. 66-78

2020

  1. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    International Journal of Gynecological Cancer

  2. COVID-19 Global Pandemic: Options for Management of Gynecologic Cancers

    Obstetrical and Gynecological Survey

  3. PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer

    Gynecologic Oncology, Vol. 159, Núm. 2, pp. 322-328

  4. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1148-1159

2019

  1. 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Thorax, Vol. 74, Núm. 4, pp. 371-379

  2. Diffusion-weighted magnetic resonance imaging in peritoneal carcinomatosis from suspected ovarian cancer: Diagnostic performance in correlation with surgical findings

    European Journal of Radiology, Vol. 121

  3. Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  4. Updates and management algorithm for neuroendocrine tumors of the uterine cervix

    International Journal of Gynecological Cancer, Vol. 29, Núm. 6, pp. 986-995

  5. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients

    Journal of Pathology, Vol. 245, Núm. 4, pp. 421-432